External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Home CHDI 2024
Roche and Genentech at

CHDI 2024

February 26 - February 29
California, USA
chdifoundation.org
Add to calendar
Share feedback
Share page
-
Medical Materials
Agenda
Coming soon
09:00 PM
Duration 3hrs California, USA
Assay susceptibility to blood contamination limits the utility of total Huntingtin (HTT) protein in cerebrospinal fluid (CSF) as a biomarker for clinical trials
David J. Hawellek
Neuroscience | Huntington's Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
10:00 PM
Duration 20mins Plenary hall
New fluid biomarker data from GENERATION HD1 and what it means for GENERATION HD2
Peter McColgan
Neuroscience | Huntington's Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar
Duration 20mins Plenary hall
Innovation in HD clinical trial design
Jonas Dorn and Marcello Boreato
Neuroscience | Huntington's Disease

You have successfully signed up for this alert. You will be notified when it is available.

Sign up or login to unlock the full suite of MEDICALLY features
Add to calendar

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.